Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis

Akt抑制剂MK2206选择性靶向CLL B细胞受体诱导的细胞因子，动员淋巴细胞，并与苯达莫司汀协同诱导CLL细胞凋亡。